MET inhibition in lung cancer Full Text
Translational Lung Cancer Research,  Review Article

Menis J. et al .– This paper aims to summarize data on Met biological function, on its interaction with cell signaling and other pathways and to present data on those Met inhibitors currently under evaluation. The discovery of new cancer–driver genes and the enforcement of molecules targeting them have changed the landscape of Non Small Cell Lung Cancer (NSCLC) treatment.As a matter of fact, the previous scenario of advanced NSCLC treatment has been completely revolutionized, switching from a “one size fits all” approach to a personalized therapy. It was concluded that Met can act as an ‘oncogene expedient’ even in absence of genetic alterations and might potentiate the effect of other oncogenes, promote malignant progression and participate in tumor angiogenesis. Met dysregulation correlates with disease prognosis in numerous cancers and represents a possible target for personalized treatment. The clinical efficacy of Met targeting agents in lung cancer needs further details from the ongoing trials as well as more information are necessary to establish the most appropriate diagnostic test to identify Met expression or amplification.

  • Met is a heterodimer receptor tyrosine kinase composed of a ?–chain and a ?–chain, linked by a disulphide bond.
  • Met was originally isolated as the product of a human oncogene, trp–met, in tumor cells treated with a chemical carcinogen.
  • Met gene encodes a 170–kD protein (p170met) that has constitutive and ligand–independent tyrosin–kinase activity.
  • Met has pivotal functions in embryogenesis and organogenesis of placenta, liver, kidney, neurons and muscles.
  • Moreover, in vivo, Met receptor activation determines a phenomenon called “invasive growth”, which includes cell proliferation, scattering, survival, motility and invasion, epithelial–mesenchymal transition and branched morphogenesis
  • In this scenario Met, a heterodimere receptor tyrosine kinase deeply involved into embryogenesis and organogenesis, has been introduced many years ago as a potential target for biological agents, becoming“druggable” only in this last period of time.
  • Met can be altered through receptor overexpression, genomic amplification, mutations or alternative splicing, autocrine or paracrine secretion of hepatic growth factor (HGF): these dysregulations stimulate tumorigenesis (in terms of cell–cell detachment, proliferation, invasion, angiogenesis and survival) and metastatization.
  • Met is overexpressed in lung cancer and Met gene amplification can drive the dependency of cell survival and proliferation upon the Met signaling. Both Met overexpression and amplification seem to correlate with poor prognosis.
  • Met amplification is also described to be linked to EGFR acquired resistance.
  • Several Met inhibitors have been tested both in preclinical and human trials, demonstrating activity in lung cancer treatment.
  • In patients with advanced NSCLC, a correct definition of the histotype is still the first step to design a proper therapeutic algorithm, but personalized molecular diagnosis is becoming more and more relevant.
  • Several molecules are currently under investigation and two of them already reached phase III trials in advanced NSCLC.

Please login or register to follow this author.
► Click here to access Full Text, PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Oncology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Oncology Articles

1 Coffee intake and gastric cancer risk Cancer Epidemiology, Biomarkers & Prevention, March 20, 2014    Clinical Article

2 The dirty side of soap UC San Diego Health System, November 20, 2014

3 Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: The Cancer-DACUS Study Journal of Clinical Oncology, October 10, 2014    Clinical Article

4 Molecular breakthrough could halt the spread of prostate cancer University of Bristol Research News, November 14, 2014

5 Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: A multicentre, open-label, phase 2 trial The Lancet Oncology, November 10, 2014    Clinical Article

6 Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer European Journal of Cancer, August 6, 2014    Clinical Article

7 Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): A randomised, multicentre, open-label, phase 3 non-inferiority trial The Lancet Oncology, October 23, 2014    Clinical Article

8 Metformin in chemotherapy-naive castration-resistant prostate cancer: A multicenter phase 2 trial (SAKK 08/09) Full Text European Urology, August 15, 2014    Free full text    Clinical Article

9 New insight on oral cancer culprits Vanderbilt University Medical Center Research News, November 17, 2014

10 Coffee plus honey versus topical steroid in the treatment of chemotherapy-induced oral mucositis: A randomized controlled trial Full Text BMC Complementary and Alternative Medicine, August 28, 2014    Free full text    Clinical Article

11 Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): A randomised, multicentre, open-label, phase 3 non-inferiority trial The Lancet Oncology, October 30, 2014    Clinical Article

12 Serum copper is a simple but valuable prognostic marker in B-cell chronic lymphocytic leukemia International Journal of Hematology, October 24, 2014    Clinical Article

13 Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer Journal of Clinical Oncology, November 19, 2014    Clinical Article

14 Phase II trial of the anti-CD19 bispecific T cell–engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia Journal of Clinical Oncology, November 17, 2014    Clinical Article

15 Smoking associated with elevated risk of developing a second smoking-related cancer American Society of Clinical Oncology (ASCO) News, November 12, 2014

16 Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial The Lancet Oncology, October 6, 2014    Clinical Article

17 Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia New England Journal of Medicine, June 4, 2014    Evidence Based Medicine    Clinical Article

18 Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: Final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12 Annals of Oncology, November 21, 2014    Clinical Article

19 Phase II randomized study of whole-brain radiation therapy with or without concurrent temozolomide for brain metastases from breast cancer Annals of Oncology, November 4, 2014    Clinical Article

20 Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: A meta-analysis Clinical Cancer Research, November 17, 2014    Evidence Based Medicine

Indexed Journals in Oncology: Journal of Clinical Oncology, Cancer Research, Annals Oncologymore